Neurontin generic
Neurontin is an anti-epileptic drug owned by Viatris that contains gabapentin as its active ingredient. First authorized for market use on 02 March, 2000, Neurontin is available in oral solution dosage forms. This drug has two patents, both of which have expired.
When will Neurontin generic be available?
The Neurontin generic versions are possible to be released after 28 November, 2022. This release date is dictated by the expiration of the patent US7256216*PED, titled 'Liquid pharmaceutical compositions', which expires on 28 November, 2022.
Neurontin uses
Neurontin is used to treat seizures and nerve pain caused by shingles. The active ingredient, gabapentin, works by reducing abnormal brain activity, thus controlling seizures. It also helps in reducing nerve pain by altering the way the body senses pain.
Neurontin patent expiration
Neurontin held a total of 2 drug patents, both of which have expired. These include US7256216, expiring on 2022-05-28, and US7256216*PED, expiring on 2022-11-28. The Neurontin generic will be possible for release post this date. Below are the details of the patents: